Enteral broad-spectrum antibiotics antagonize the effect of fecal microbiota transplantation in preterm pigs.
Animals
Animals, Newborn
Anti-Bacterial Agents
/ administration & dosage
Bacterial Adhesion
/ drug effects
Combined Modality Therapy
Disease Models, Animal
Drug Resistance, Microbial
/ drug effects
Enterocolitis, Necrotizing
/ immunology
Fecal Microbiota Transplantation
Gastrointestinal Microbiome
/ drug effects
Immunity, Mucosal
/ drug effects
Intubation, Gastrointestinal
Lymphocytes
/ drug effects
Myeloid Cells
/ drug effects
Premature Birth
Swine
Treatment Outcome
Gut microbiota
antibiotics
antibiotics resistance
fecal microbiota transplantation
immunity
necrotizing enterocolitis
prematurity
Journal
Gut microbes
ISSN: 1949-0984
Titre abrégé: Gut Microbes
Pays: United States
ID NLM: 101495343
Informations de publication
Date de publication:
Historique:
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
15
1
2022
Statut:
ppublish
Résumé
Preterm infants are at risk of multiple morbidities including necrotizing enterocolitis (NEC). Suspected NEC patients receive intravenous antibiotics (AB) to prevent sepsis, although enteral AB is arguably more effective at reducing NEC but is rarely used due to the risk of AB resistance. Fecal microbiota transplantation (FMT) has shown protective effects against NEC in animal experiments, but the interaction between AB and FMT has not been investigated in neonates. We hypothesized that administration of enteral AB followed by rectal FMT would effectively prevent NEC with negligible changes in AB resistance and systemic immunity. Using preterm piglets, we examined host and gut microbiota responses to AB, FMT, or a sequential combination thereof, with emphasis on NEC development. In a saline-controlled experiment, preterm piglets (n = 67) received oro-gastric neomycin (50 mg/kg/d) and amoxicillin-clavulanate (50/12.5 mg/kg/d) (hereafter AB) for four days after cesarean delivery, and were subsequently given rectal FMT from healthy suckling piglet donors. Whereas AB protected the stomach and small intestine, and FMT primarily protected the colon, the sequential combination treatment surprisingly provided no NEC protection. Furthermore, minor changes in the gut microbiota composition were observed in response to either treatment, although AB treatment decreased species diversity and increased AB resistance among coliform bacteria and Enterococci, which were both partly reversed by FMT. Besides, enteral AB treatment suppressed cellular and functional systemic immune development, which was not prevented by subsequent FMT. We discovered an antagonistic relationship between enteral AB and FMT in terms of NEC development. The outcome may depend on choice of AB compounds, FMT composition, doses, treatment duration, and administration routes, but these results challenge the applicability of enteral AB and FMT in preterm infants.
Identifiants
pubmed: 33382952
doi: 10.1080/19490976.2020.1849997
pmc: PMC7781584
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-16Références
N Engl J Med. 2011 Jan 20;364(3):255-64
pubmed: 21247316
Front Microbiol. 2020 May 19;11:932
pubmed: 32508773
J Microbiol Methods. 2018 Jan;144:1-7
pubmed: 29107603
Front Microbiol. 2017 Jun 28;8:1208
pubmed: 28702022
ISME J. 2019 Mar;13(3):720-733
pubmed: 30367124
Microbiome. 2016 Dec 29;4(1):67
pubmed: 28034304
Cell. 2018 Sep 6;174(6):1406-1423.e16
pubmed: 30193113
Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G855-G867
pubmed: 30118350
J Pediatr. 2018 Dec;203:62-67
pubmed: 30172430
Clin Infect Dis. 2016 Jun 15;62(12):1479-1486
pubmed: 27025836
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12522-7
pubmed: 25114261
Front Microbiol. 2020 Jul 07;11:1319
pubmed: 32733394
J Pediatr. 2020 Dec;227:128-134.e2
pubmed: 32553865
Microbiome. 2017 Jul 12;5(1):75
pubmed: 28701177
Cell Host Microbe. 2015 May 13;17(5):662-71
pubmed: 25865369
Sci Rep. 2018 Feb 6;8(1):2453
pubmed: 29410448
Nat Med. 2019 Nov;25(11):1772-1782
pubmed: 31700190
Am J Physiol Regul Integr Comp Physiol. 2016 Mar 15;310(6):R481-92
pubmed: 26764054
Gut Microbes. 2017 May 4;8(3):208-213
pubmed: 28318396
Nat Med. 2014 May;20(5):524-30
pubmed: 24747744
Infect Drug Resist. 2019 Nov 27;12:3695-3702
pubmed: 31819551
Gastroenterology. 2012 Sep;143(3):708-718.e5
pubmed: 22796522
JPEN J Parenter Enteral Nutr. 2016 May;40(4):552-66
pubmed: 25613990
Microbiome. 2017 Mar 9;5(1):31
pubmed: 28274256
Arch Dis Child Fetal Neonatal Ed. 1998 Sep;79(2):F105-9
pubmed: 9828735
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Clin Chem Lab Med. 2015 Jul;53(8):1181-8
pubmed: 25720080
Cochrane Database Syst Rev. 2001;(1):CD000405
pubmed: 11279690
Pediatrics. 2009 Jan;123(1):58-66
pubmed: 19117861
J Pediatr. 2014 Jul;165(1):23-9
pubmed: 24529620
Sci Rep. 2016 May 16;6:25497
pubmed: 27180802
Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G59-71
pubmed: 24157972
Am J Physiol Gastrointest Liver Physiol. 2016 Mar 1;310(5):G323-33
pubmed: 26680737
Clin Infect Dis. 2020 Jun 10;70(12):2553-2560
pubmed: 31367771
Antimicrob Agents Chemother. 2013 Aug;57(8):3659-66
pubmed: 23689712
Cell Host Microbe. 2014 Mar 12;15(3):374-81
pubmed: 24629343
Microbiome. 2017 Dec 11;5(1):158
pubmed: 29228972
Front Microbiol. 2017 Dec 11;8:2430
pubmed: 29321764